Group 1: Financial Performance - The company's revenue and net profit declined in 2025 due to macroeconomic conditions, industry cycles, and market competition, with the raw material pharmaceutical intermediate business being the primary factor affecting revenue [3] - The company expects to release its Q1 report on April 21, 2026 [3] - Contract liabilities significantly decreased, indicating revenue conversion rather than a loss of orders, which does not directly impact future performance [2] Group 2: Business Strategy and Growth - The CDMO (Contract Development and Manufacturing Organization) business is anticipated to be the main driver of performance growth in the next 1-2 years [4] - The company is focusing on expanding its CDMO business in veterinary medicine, benefiting from the global demand for animal health care [4] - The company plans to continue increasing R&D investment, maintaining it at around 6% of revenue, to support sustainable business development [3] Group 3: Product Development and Market Expansion - The company has completed clinical enrollment for the drug Semaglutide for weight loss and diabetes, adhering to regulatory processes to expedite product launch [2] - The company is developing new products in the medical beauty sector, leveraging its chemical synthesis and synthetic biology platforms [4] - The new peptide workshop is under construction and will meet commercial production needs for peptide projects once operational [5] Group 4: Market Position and Competition - The company aims to maintain and enhance its market share through effective market expansion and customer relationship management, focusing on cost and quality competitiveness [4] - The CDMO business's gross margin rose to over 48% in Q4 2025, with efforts to maintain or improve this margin through technology upgrades and cost control [5] - The company is expanding its overseas market presence, with expected increases in sales volume, although profitability will be influenced by market competition [5]

证券代码：000739 证券简称：普洛药业 公告编号：2026-26 一、担保情况概述 1、2026 年 3 月 13 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司昌邑支行签订《最高额保证合同》（合同编号：2026 年昌 邑总保字 005 号），同意为公司全资子公司山东普洛得邦医药有限公司提供最高 额 10,000 万元的连带责任保证，担保期限为三年。 2、2026 年 3 月 23 日，公司与招商银行股份有限公司金华义乌支行（以下 简称"招商银行"）签订《不可撤销担保书》（合同编号：571HT260319T00032101）, 同意为公司全资子公司浙江普洛家园药业有限公司与招商银行签署的《借款合同》 （合同编号：571HT260319T000321）提供流动资金借款 1,000 万元连带责任保证， 担保期限为 12 个月。 3、2026 年 3 月 24 日，公司与中国银行股份有限公司东阳支行（以下简称 "中国银行东阳支行"）签订《保证合同》（合同编号：横店 2026 年人保字 072 号），同意为公司控股子公司浙江普洛康裕制药有限公司与中国银行东阳支行签 署的《商业汇票承兑协议》（ ...

2、剂型：注射剂 证券代码：000739 证券简称：普洛药业 公告编号：2026-25 普洛药业股份有限公司 关于获得药品注册证书及化学原料药上市申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局（以下简称"药监局"）签发的硫酸麻 黄碱注射液《药品注册证书》以及硫酸麻黄碱原料药的《化学原料药上市申请批 准通知书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：硫酸麻黄碱注射液 3、规格：1ml:50mg 4、注册分类：化学药品 3 类 5、上市许可持有人：浙江普洛康裕制药有限公司 6、生产企业：浙江普洛康裕制药有限公司 7、证书编号：2026S00775 8、药品批准文号：国药准字 H20263649 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、化学原料药上市申请批准情况 1、化学原料药名称：硫酸麻黄碱 2、申请事项：境内生产化学原料药上 ...

关于控股股东一致行动人增持公司股份计划实施完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：000739 证券简称：普洛药业 公告编号：2026-24 普洛药业股份有限公司 1.普洛药业股份有限公司（以下简称"公司"）于2026年1月14日披 露了《关于控股股东一致行动人增持公司股份暨权益变动触及1%整数倍及 后续增持计划的公告》（公告编号：2026-04），控股股东横店集团控股 有限公司之一致行动人东阳市横店禹山运动休闲有限公司（以下简称"禹 山运动"）于2026年1月13日，通过深圳证券交易所交易系统以集中竞价 交易方式增持公司股份1,653,500股，占公司总股本的0.14%，增持金额共 计人民币28,695,970元，公司控股股东及其一致行动人合计持有公司股份 比例达到52.03%，权益变动触及1%整数倍。 2.禹山运动计划自2026年1月13日起6个月内，以自有资金或自筹资金 通过集中竞价交易方式增持公司股份，拟增持公司股份金额不低于人民币 0.6亿元（包含本次已增持的28,695,970元），不超过人民币1.2亿元（ ...

法 律 意 见 书 康达法意字[2026]第 0107 号 二〇二六年三月 法律意见书 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于普洛药业股份有限公司 控股股东一致行动人增持公司股份事宜的 北京市康达律师事务所 关于普洛药业股份有限公司 控股股东一致行动人增持公司股份事宜 的法律意见书 康达法意字[2026]第 0107 号 致：普洛药业股份有限公司 北京市康达律师事务所（以下简称为"本所"）接受普洛药业股份有限公司（以 下简称"公司"或"普洛药业"）的委托， ...

Investment Rating - The report maintains a "Strong Buy" rating for Prolo Pharmaceutical (000739) [1] Core Views - The company's performance in 2025 met expectations, with revenue of 9.784 billion yuan (-18.62%) and net profit attributable to shareholders of 891 million yuan (-13.62%) [1] - The CDMO (Contract Development and Manufacturing Organization) business is expected to enter a rapid growth phase, with projected revenue growth of 16.66% in 2026 [7] - The company has a healthy project pipeline with 1,311 ongoing projects, including 398 in the commercialization phase and 913 in the R&D phase [7] Financial Summary - Total revenue for 2025 was 9,784 million yuan, with a year-on-year decline of 18.6% [3] - Net profit attributable to shareholders for 2025 was 891 million yuan, down 13.6% year-on-year [3] - The company expects a recovery in the pharmaceutical business, with projected revenues of 11.50 billion yuan in 2025, a decrease of 8.42% year-on-year [7] - The projected net profit for 2026 is 1,075 million yuan, with a growth rate of 20.6% [3] - The target price for the stock is set at 23 yuan, based on a 25x PE ratio for 2026 [7]

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [1][22]. Core Insights - The company's 2025 financial results met expectations, with total revenue of 9.784 billion yuan, a decrease of 18.62% year-on-year, and a net profit attributable to shareholders of 891 million yuan, down 13.62% [1][3]. - The CDMO (Contract Development and Manufacturing Organization) business is anticipated to enter a rapid growth phase, with revenue from this segment reaching 2.198 billion yuan in 2025, reflecting a year-on-year increase of 16.66% [7][8]. - The company has a healthy project pipeline with 1,311 ongoing projects, including 398 in the commercialization phase and 913 in the research phase, indicating strong future growth potential [7][8]. Financial Performance Summary - In Q4 2025, the company reported revenue of 2.020 billion yuan, a decline of 26.06%, but a net profit of 190 million yuan, an increase of 17.92% [1]. - The projected revenue for 2026 is estimated at 10.536 billion yuan, with a year-on-year growth rate of 7.7% [3]. - The company plans to distribute a total of 821 million yuan in cash dividends and share buybacks, representing 92.19% of the net profit for 2025 [1]. Future Projections - The company is expected to see a rebound in its pharmaceutical business, with projected revenues of 1.150 billion yuan in 2025, down 8.42% year-on-year, but with a gross margin of 61.55% [7]. - The net profit forecasts for 2026, 2027, and 2028 are 1.075 billion yuan, 1.295 billion yuan, and 1.629 billion yuan, respectively, indicating a recovery trajectory [8]. - The target price for the stock is set at 23 yuan, based on a projected price-to-earnings ratio of 25 times for 2026 [7][8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The CDMO segment has become the largest contributor to the company's gross profit, surpassing the API segment, and is expected to continue its high growth into 2026, while the API segment is anticipated to recover from its bottom [1][3] - The company reported a revenue of 9.784 billion yuan in 2025, a year-over-year decrease of 18.62%, with a net profit attributable to shareholders of 891 million yuan, down 13.62% year-over-year [2] - The CDMO business achieved a revenue of 2.198 billion yuan in 2025, reflecting a year-over-year growth of 16.66%, with a total of 1,311 ongoing projects, a 32% increase from the previous year [3] - The pharmaceutical business generated a revenue of 1.150 billion yuan in 2025, down 8.42% year-over-year, with a focus on a multi-variety development strategy [4] - The overall gross margin for 2025 was 26.36%, an increase of 2.51 percentage points year-over-year, with the CDMO segment's gross margin at 45.24%, up 4.18 percentage points [5] Financial Performance - The company generated an operating cash flow of 1.22 billion yuan in 2025, showing a year-over-year increase of 0.95%, indicating good operational quality [2] - The projected earnings per share (EPS) for 2026-2028 are expected to be 0.92, 1.09, and 1.29 yuan respectively, with a price-to-earnings (P/E) ratio of 18 times for 2026 [11]

一、公示情况说明 证券代码：000739 证券简称：普洛药业 公告编号：2026-23 普洛药业股份有限公司 董事会薪酬与考核委员会关于公司 2026 年股票期权激励计 划首次授予部分激励对象名单的公示情况说明及核查意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2026 年 3 月 10 日，普洛药业股份有限公司（以下简称"公司"） 第九届董事 会第十八次会议、董事会薪酬与考核委员会 2026 年第一次会议审议通过了《关 于<普洛药业股份有限公司 2026 年股票期权激励计划（草案）>及摘要的议案》 等相关议案。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"） 《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》等相关规定，公 司对《2026 年股票期权激励计划（草案）》（以下简称"《激励计划》"）拟首次 授予部分激励对象名单在公司内部进行了公示。公司董事会薪酬与考核委员会结 合公示情况对拟激励对象进行了核查，相关公示情况及核查情况如下： 1、公示内容：本激励计划拟首次授予激励对象的姓名及职务。 2、公示时间：2026 年 3 月 ...

证券代码：000739 证券简称：普洛药业 公告编号：2026-22 普洛药业股份有限公司 普洛药业股份有限公司（以下简称"公司"）已于 2026 年 3 月 20 日在《证 券时报》和巨潮资讯网（www.cninfo.com.cn）披露公司 2025 年年度报告。为进 一步加强与投资者的深入交流，使投资者更加全面、深入地了解公司情况，公司 将于 2026 年 3 月 31 日（星期二）下午 15：00-16：00 通过易董价值在线平台 （www.ir-online.cn）举行 2025 年度业绩说明会。 一、说明会类型 本次业绩说明会以网络方式召开，公司将针对 2025 年度业绩和经营情况相 关事宜与投资者进行互动交流，在信息披露允许的范围内就投资者普遍关注的问 题进行回答。 二、说明会召开的时间、地点 三、参加人员 总经理何春先生、独立董事钱娟萍女士、副总经理兼董事会秘书周玉旺先生、 财务总监张进辉先生、董事会办公室主任兼证券事务代表关键先生。 四、投资者参加方式 （1）投资者可通过网址 https://eseb.cn/1wE853QBMCk 或使用微信扫描下 方小程序码即可进入参与互动交流。 关于举行 ...